Doctor at Cardiology department, Lariboisiere Saint Louis University of Paris, France
Dr. Martin Nicol is a distinguished French cardiologist with a specialization in cardio-oncology, cardiac imaging, and cardiovascular diseases. With over a decade of experience in both clinical and academic roles, he has made significant contributions to cardiology through his research, teaching, and clinical expertise. His work has garnered recognition at international conferences, and he continues to lead in the development of specialized cardiac care.
Profile:
SCOPUS
Education:
Dr. Nicol’s educational journey is rooted in some of France’s most prestigious institutions. He completed his medical degree from Université Paris 7 in 2018, where he also earned a Doctorate in Medicine. His postdoctoral training includes a DES in cardiology and vascular diseases from Université Paris 6. Dr. Nicol further specialized by obtaining several diplomas, including a DIU in cardio-oncology and echocardiography. His extensive academic background provided a solid foundation for his later research and clinical endeavors.
Experience:
Dr. Nicol’s professional experience spans across leading hospitals in Paris, where he served as an intern and later as a fellow in multimodal cardiac imaging at the Centre Cardiologique du Nord. He gained valuable experience in echocardiography, MRI, and cardiac scanning. From 2019 to 2021, he was the Chief of Clinic in the cardiology department at Lariboisière Hospital, where he developed specialized consultations in cardio-oncology. In 2022, he transitioned to private practice, joining the Maison Médicale de Mareil Marly and Ambroise Paré Hospital. Dr. Nicol also continues his work at Saint Louis Hospital, specializing in the treatment of amyloidosis.
Research Interest:
Dr. Nicol’s research is deeply centered on cardiovascular diseases, specifically focusing on cardiac amyloidosis, cardio-oncology, and cardiac imaging. His doctoral thesis on myocardial stiffness in heart failure highlighted his commitment to advancing diagnostic and treatment methods for complex cardiovascular conditions. He has collaborated with international research groups to further explore these areas, particularly in the integration of imaging modalities and their prognostic values.
Awards:
Dr. Nicol has received numerous accolades for his contributions to cardiology research. Notable among these is the Young Investigator Award at the Global Cardio-Oncology Summit in 2018 for his diagnostic score of cardiac involvement in AL amyloidosis. He also won several awards for his work on the cardiotoxicity induced by doxorubicin and trastuzumab, including the Best Oral Communication Award at GRRC 2018 and Best Poster Award at JFIC 2018.
Publications:
Dr. Nicol has published extensively in reputable cardiology journals. His work spans topics from subclinical left ventricular dysfunction during chemotherapy to the prognosis of cardiac amyloidosis. Some of his key publications include:
Nicol M, Deblaise J, Choussat R, Dubourg O, Mansencal N. “Side effects of ticagrelor: sinus node dysfunction with ventricular pause.” Int J Cardiol, 2015. Cited by 56 articles.
Nicol M, Baudet M, Cohen Solal A. “Subclinical left ventricular dysfunction during chemotherapy.” Card Fail Rev, 2019. Cited by 45 articles.
Nicol M, Cescau A, Baudet M, Harel S, Royer B. “Prognostic value of 123-I MIBG in AL amyloidosis.” Circ Cardiovasc Imaging, 2019. Cited by 38 articles.
Nicol M, Deney A, Lairez O, Vergaro G, Emdin M. “Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.” Eur J Heart Fail, 2021. Cited by 29 articles.
Nicol M, Sadoune M, Azibani F. “Doxorubicin and trastuzumab induced cardiotoxicity in mice is not prevented by metoprolol.” ESC Heart Fail, 2021. Cited by 22 articles.
Nicol M, Siguret V, Vergaro G. “Thrombo-embolism and bleeding in patients with amyloidosis: A review.” ESC Heart Fail, 2022. Cited by 16 articles.
Nicol M, Hubert A, Coisne A. “Reproducibility of the 2016 American Society of Echocardiography-Algorithm for Estimation of Left Ventricular Filling Pattern.” Ultrasound Med Biol, 2022. Cited by 12 articles.
Nicol M, Vergaro G, Damy T. “Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis.” Front Cardiovasc Med, 2023. Cited by 10 articles.
Conclusion
Dr. Martin Nicol’s research contributions, particularly in the field of cardio-oncology and cardiac amyloidosis, make him a strong candidate for the Best Research Paper Award. His impressive record of publications, awards, and innovative research in multimodal cardiac imaging align well with the award’s criteria. Expanding his clinical trial work and focusing on mentorship could further enhance his qualifications, but his current profile already demonstrates a remarkable level of expertise and impact.